The triple therapy showed a 50% overall response rate and 22-month median overall survival in MSS BRAF V600E-mutant mCRC patients. Targeting MAPK signaling with encorafenib and cetuximab may prime ...
ARCHER II trial evaluates vonaprument's efficacy in preventing vision loss in advanced AMD/GA, with over 630 patients enrolled globally. Vonaprument selectively inhibits C1q, addressing ...
Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
This important work advances our understanding of factors influencing efficacy assessments and biomarker viability for complement-directed gene therapy against age-related macular degeneration. The ...
A growing body of evidence suggests that complement dysregulation plays a role in the pathogenesis of preeclampsia. The kidney is one of the major organs affected in preeclampsia. Because the kidney ...
Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...
CNS-compartmentalized complement activation contributes to MS progression and severity, according to data published in Neurology Journals. To investigate complement activation in MS in the context of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results